

Atty. Docket No. PG4114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE: Application of Karl Andrew GARRILL, et al.

Serial No.: 09/599,274

Art Unit: 3728

Filing Date: 06/22/2000

Examiner: Jerrold JOHNSON

For: Method and Package for Storing a Pressurized Container Containing a Drug

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the following references are enclosed. References # 9-17
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☒ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.


☒ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Michael Strickland, Attorney of Record
Registration No. 47,115

Date: November 22, 2005
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9024
Facsimile: (919) 483-5730

FORM PTO-148 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG4114		SERIAL NO. 09/599,274	
				APPLICANT: Karl Andrew GARRILL, et al.			
				FILING DATE: 06/22/2000		GROUP 3728	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	3,704,806	12/05/1972	PLACHENOV, et al.			
	2.	4,042,170	08/16/1977	EKMAN, et al.			
	3.	4,363,841	12/14/1982	SNOW			
	4.	4,841,297	06/20/1989	BOURGEAUX			
	5.	4,861,632	08/29/1989	CAGGIANO			
	6.	5,261,538	11/16/1993	EVANS, et al.			
	7.	5,763,028	06/09/1998	MATSUMOTO, et al.			
	8.	6,679,374	01/20/2004	GARRILL, et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	9.	2005538	04/25/1979	GB			
	10.	93/09038	03/13/1993	PCT			√ (Abstract)
	11.	94/26624	11/24/1994	PCT			√ (Abstract)
	12.	8243148	09/24/1996	JP			√ (Abstract)
	13.	96/32099	10/17/1996	PCT			
	14.	96/32150	10/17/1996	PCT			
	15.	96/32151	10/17/1996	PCT			
	16.	96/32345	10/17/1996	PCT			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	17.	Williams, Gerallt and Tcherevatchenkoff, A. (1998) "Moisture Transport Into CFC-Free MDIs," Respiratory Drug Delivery VI, Vol 1, pp 471-474 (1998).					
	18.	Serial No. : 09/971,799 filed 10/03/2001					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							